This area of our website is for healthcare professionals only

Please click below to declare your professional status:

YES, I am a healthcare professional  NO, I am not a healthcare professional

Conference Programme

Wednesday 7 July 2021

10:00 - 11:00

Virtual exhibition & networking

11:00

Conference opening remarks

Dr Peter GREEN (Chairman, HEART UK)

 

Session 1: FH or not?

11:05 - 11:45

Introduction and Interactive cases linked to

Ms Kate HARALAMBOS (Cardiff, Wales, UK)


Polygenic hypercholesterolaemia: why do we want to know?
How knowing that a patient with clinical FH has a polygenic and not a monogenic cause for their phenotype is key in the clinician deciding on the appropriate patient care pathway

Prof Steve HUMPHRIES (London, UK)


VUS in FH

Dr Maggie WILLIAMS (Bristol, UK)

 

11:45 - 12:00

Break, virtual exhibition & networking

 

Session 2: Hyperlipidaemia educational updates

 

Co-chairs: Julian HalcoxHandrean Soran

12:00 - 12:20

Cardiac CT; the future of imaging

Why cardiac CT is useful for those with patients with raised cholesterol

Dr Derek CONNOLLY (Birmingham, UK)

12:20 - 12:40

Urine chemical medication analysis in the assessment of medication adherence

The presentation will cover the  how, the why and the when of using the test

Dr Pankaj GUPTA (Leicester, UK)

12:40 - 13:00

 

The impact of metabolic surgery on obesity related dyslipidaemia

Dr Safwaan ADAM (Manchester, UK)

 

13:00 - 13:40

Lunch, virtual exhibition & networking

 

Session 3: Lp(a)… what does it mean ?

 

Co-chairs: Jai Cegla + Dev Datta

13:40 - 14:00

Lp(a) measurement bias 

Over and underestimation of Lp(a) due to its different molecular weight isoforms has led to bias in many studies leading to underestimation of its strength as a cardiovascular risk factor

Dr Mike FRANCE (Manchester, UK)

14:00 - 14:20

How does Lp(a) fit with FH

Prof Paul DURRINGTON (Manchester, UK)

14:20 - 14:55

The role of Lp(a) and oxPLs in atherosclerosis

Current and future therapeutic agents and interventions targeting Lp(a) and oxPLs

Prof Sam TSIMIKAS (San Diego, USA)

14:55 - 15:15

Break, virtual exhibition & networking

 

Chair: Alan Rees

15:15 - 16:15

Session 4: Myant lecture:

Heterozygous Familial Hypercholesterolaemia – From Phenotype to Genotype: A Paradigm Shift?

Clinical Certainties and Uncertainties: what remains unresolved?

Prof Andrew NEIL (Oxford, UK)

16:15

Day one close

 

View on demand

Tuesday 13 July 2021

   

Primary & Health Care - Abstracts of free communications

 

Co-chairs: Chris Allen + Nadeem Qureshi

 

6                                                                                

16:25 - 16:32                               

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis                                                      

Steve Humphries (London, UK)

 

16:32 - 16:35  Discussion                                        

 

7                                                                                

16:35 - 16:42                               

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care

Barbara Iyen (Nottingham, UK)

 

16:42 - 16:45   Discussion                                       

                                                      

8                                                                                

16:45 - 16:52                               

Identifying familial hypercholesterolemia (FH) in Hampshire general medical practices: a systematic approach – Interim Results               

Jayne Haigh (Hampshire, UK)

 

16:52 - 16:55  Discussion                                        

 

9

16:55 - 17:02                               

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records                                                      

Steve Humphries  (London, UK)

 

17:02 - 17:05  Discussion                                        

 

10                                                                              

17:05 - 17:12                               

The West Midland Familial Hypercholesterolaemia (FH) screening programme: Evaluating the utility of the 12 SNP polygenic risk score (PRS) across ethnic groupings                                                      

Maggie Williams  (Bristol, UK)

 

17:12 - 17:15   Discussion 

 

 

17:15 - 17:35

Break, virtual exhibition & networking

 

17:35 - 18:05

 

 

Sponsored symposium 1: 

Add on to take back control. Do we have the solutions to the gaps in our lipid treatment pathway?

 

Chair: Dr Derek CONNOLLY (Cardiologist, Birmingham, UK)

 

SpeakerDr Susan CONNOLLY (Cardiologist, Enniskillen, N Ireland)

 

 

This promotional symposium has been organised and sponsored by Daiichi Sankyo UK

This symposium will be available to view on demand in the coming weeks.

 

18:05

Day two close

 

View on demand

Thursday 15 July 2021

15:00 - 15:45

Virtual exhibition & networking

15:45 - 15:50

Welcome

15:50 - 16:20

Moderated poster session

 

Session moderators: Mike Khan + Alison Pottle

 

1

15:50 - 15:52                               

Absence of coronary artery calcium does not exclude coronary artery disease in FH patients

Alisha Israni (London, UK)

 

15:52 - 15:55  Q&A                                                                            

                                                      

2                                                                                                          

15:55 - 15:57                            

Lipoprotein (a) levels in monogenic versus polygenic hypercholesterolemia

Anjly Jain  (London, UK)

 

15:57 - 16:00  Q&A                                                                            

 

3                                                                                                          

16:00 - 16:02                              

Severe dyslipidaemia associated with dual heterozygosity for 2 genes causing hyperalpalipoproteinaemia

Eun Ji Kim  (London, UK)

 

16:02 - 16:05  Q&A                                                                            

 

4                                                                                                          

16:05 - 16:07                               

Prospective evaluation of the FAMCAT tool to identify Familial Hypercholesterolaemia (FH) in primary care

Arushan Kirubakaran  (London, UK)

 

16:07 - 16:10  Q&A

                                                                                                             

5                                                                                                          

16:10 - 16:12                              

The diagnostic yield for FH proband genetic testing is lower in postmenopausal women when fixed LDL-C decision thresholds are used                                                      

Ahai Luvai  (Newcastle, UK)

 

16:12 - 16:15  Q&A                     

                                                      

6                                                                                                          

16:15 - 16:17                              

Inpatient management of severe hypertriglyceridaemia at a tertiary centre

Wei Yang  (London, UK)

 

16:17 - 16:20  Q&A                                                                            

 

 

Session 6:  

 

Co-chairs: Alan FlanaganMike France

16:20 - 16:44

Saturated fats and health

Prof Ian YOUNG (Belfast, N Ireland)

16:45 - 17:20

Breaking barriers in lipid management

Victoria SPELLACY, Accelerated Access Collaborative Senior Manager for Rapid Uptake Products
Dr Joe CHIDANYIKA (PhD), AAC / AHSN National Programme Manager (Lipid and FH Programme)

17:20 - 17:40

Break, virtual exhibition & networking

17:40 - 18:10

Sponsored symposium 2

Closing the gap in cholesterol management: A healthcare system approach

 

Don’t miss Dr Derek Connolly, Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer, Birmingham City Hospital and Dr Peter Carey, Consultant in Diabetes and Endocrinology, South Tyneside and Sunderland, discuss the role of LDL-C and Lp(a) as independent risk factors for ASCVD, and how population health management could help tackle the cholesterol problem at a healthcare system level. They will also talk about guideline recommendations in terms of LDL-C-lowering and Lp(a) testing, focusing on the gap between LDL-C targets and results, and the current underutilisation of Lp(a) testing when assessing at-risk patients.

 

 Hosted by

 

ASCVD – atherosclerotic cardiovascular disease; LDL-C – low-density lipoprotein cholesterol; Lp(a) – lipoprotein(a)

 

134821 June 2021

18:10

Day two close

18:15 - 18:45

Networking chats
Grab a drink and hop onto a networking chat table.

These will offer an informal opportunity for groups of 10 people to sit on one of a selection of 10 virtual tables to chat and network (seating is first come, first served), discuss the presentations, exchange experiences over a cup of something hot or cold.  Everyone will be connected by their webcam and microphone.

These will be either topic led or open networking chat tables. Tables will be hosted by a moderator to help kick start the conversation.

 

Tuesday 20 July 2021 

15:00 - 15:45

Virtual exhibition & networking

 

Session 7: The Essential Cholesterol Programme for Primary Care + Allied Health Professionals

 

Session sponsored by:

 

Co-chairs: Chris Allen + Michaela Nuttall + Ben Jones

15:45 - 16:00

An introduction to the basics of cholesterol 

A cholesterol refresher with easy ways to remember what cholesterol is and why we need it.

Ms Michaela NUTTALL (Bromley, UK)

16:00 - 16:15

Understanding cholesterol results 

This presentation aims to outline how primary care should evaluate lipid results. 

The aim is not to know all the answers but not to miss any of the problems.

Dr Pete GREEN (Medway, UK)

 

Spotlight on diet and its impact on cholesterol

16:15 - 16:25

The impact of diet on cholesterol 
Mr Alan FLANAGAN (Surrey, UK)

16:25 - 16:35

Diet and cholesterol: from science to practice

Ms Lynne GARTON  (London, UK)

16:35 - 16:45

Joint discussion

16:45 - 17:00

Diabetes and cholesterol: exploring dietary factors

Ms Emma ELVIN (London, UK)

17:00 - 17:15

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects: The SAMSON Trial

60 patients with previous statin side effects were given alternating periods of statin, placebo and no treatment to determine what proportion of their side effects are due to the nocebo effect.

Dr James HOWARD (London, UK)

17:15 - 17:30

Break, virtual exhibition & networking

17:30 - 18:00

Sponsored symposium 3

Don’t miss this engaging 30-minute session with Dr Nigel Capps, Consultant Chemical Pathologist, Telford, and Chair of the conference organising committee, and Professor Kausik K. Ray, President of the European Atherosclerosis Society, Professor of Public Health and Honorary Consultant Cardiologist, who will be discussing inclisiran - a first in class LDL-C lowering therapy, with the convenience of two maintenance doses a year.* Learn about the Phase III data of inclisiran and its role in helping to tackle the cholesterol problem in the UK. Following the discussion there will be the opportunity to take part in an interactive Q&A.

 

* After an initial dose, inclisiran is administered again at 3 months, followed by every 6 months.[1-3]

 

Click here for full prescribing information and adverse event reporting.

Inclisiran is not yet available to prescribe in the UK.

 

Adverse Event Reporting: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com

 

References

[1]. Leqvio® Summary of Product Characteristics. [2]. Stoekenbroek RM et al. Future Cardiol 2018;14(6):433-442. [3]. Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.

 

134823 June 2021

 

This is a promotional symposium sponsored by Novartis Pharmaceuticals UK Ltd.

18:00

Day three close

18:05 - 18:35

Networking chats
Grab a drink and hop onto a networking chat table.

These will offer an informal opportunity for groups of 10 people to sit on one of a selection of 10 virtual tables to chat and network (seating is first come, first served), discuss the presentations, exchange experiences over a cup of something hot or cold.  Everyone will be connected by their webcam and microphone.

These will be either topic led or open networking chat tables. Tables will be hosted by a moderator to help kick start the conversation.

 

 

Thursday 22 July 2021

15:00 - 15:25

Virtual exhibition & networking

15:25 - 15:30

Introduction

15:30 - 16:30

Sponsored symposia 4

 

Part 1:  15:30 - 16:00

NICE vs European LDL-C recommendations: Which one to follow?

Dr Yassir JAVAID + Dr Handrean SORAN

 

 

Please join Dr. Yassir Javaid and Dr. Handrean Soran who will offer specialist perspectives from both primary and secondary care as they discuss bringing LDL-C levels as low as possible and as quickly as possible in high risk CV patients. They will also be examining the difference between the most recent ESC/EAS guidelines and the NICE guidelines for high and very high risk CV patients with hypercholesterolaemia and how we can bridge the gap between these two guidelines.

 

GB-REP-0621-00026 Date of Preparation: July 2021

 

This promotional symposium is organised and hosted by Amgen and intended for GB HCP’s


 Part 2: 16:00 - 16:30

Treating to target in homozygous familial hypercholesterolaemia 
The Birmingham experience – improving outcomes and quality of life, a perspective through the eyes of a clinician and a patient

 

Find out more...

 

Hosted by 

 

16:30 - 16:45

Break, virtual exhibition & networking

 

Session 8: Scientific session + hot topics

 

Co-chairs: Nigel Capps + Dermot Neely

16:45 - 16:50

Introduction 

16:50 - 17:10

Covid - it’s impact on healthcare

COVID and the response to COVID has had a wider health impact on the population and the legacy impact of care needs, than the virus itself.

This presentation aims to outline some of those impacts, particularly in relation to cardiovascular disease, and what's being done to address these issues. 

Dr Pete GREEN (Medway, UK)

17:10 - 17:30

NICE Guidelines and Technology Appraisals: How Does it Work?

Overview of the processes by which NICE devises guidelines, does drug technology and diagnostic assay appraisals.

Prof Tony WIERZBICKI (London, UK)

17:30 - 17:50

FH and the NHS LTP commitment 

The presentation will cover the ambition of the NHS Long Term Plan as it relates to familial hypercholesterolaemia and the progress made to date.

Prof Nick LINKER (London, UK)

17:50 - 18:00

Announcement of the Rianna Wingett award winners

Announcement of the oral abstracts of free communications winners 

Announcement of the poster prize winners x 2

Dr Alan REES

 

Conference closing remarks

Dr Peter GREEN (Chairman, HEART UK)
Day four close

Final programme. The organisers reserve the right to change the programme at any time.